Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of NBI-1070770 in adults with Major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• NBI-1070770

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED